Drugs / Mizagliflozin
Mizagliflozin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05721729 | Jun 2023 → May 2024 | post-surgical hypoinsulinemia | Vogenx, Inc. | Completed | Met primary |
| Phase 2 | NCT05541939 | Sep 2022 → Feb 2023 | post-surgical hypoinsulinemia | Vogenx, Inc. | Completed | Met primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-06-26 | Vogenx, Inc. | Results Vogenx Announces Positive Results From Second Phase 2 Study of Mizagliflozin in Post-Bariatric Hypoglycemia vogenx.com ↗
Vogenx, a clinical-stage developer of novel therapeutics for the treatment of serious metabolic and gastrointestinal diseases, today announced positive results from study VGX 001-012 evaluating Mizagliflozin in patients diagnosed with post-bariatric hypoglycemia (PBH). |
| 2023-06-30 | Vogenx, Inc. | Results Vogenx Announces Positive Results in Phase 2 Study of Mizagliflozin in Post-Bariatric Hypoglycemia vogenx.com ↗
Vogenx, a clinical-stage developer of novel therapeutics for the treatment of metabolic disease, today announced positive results from study VGX 001-011 (NCT05541939). |
All press releases naming this drug 9 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mizagliflozin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05721729 ↗ |
| Known as | Dsp-3235 free base | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314923 ↗ |
| Known as | Gsk-1614235 free base | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314923 ↗ |
| Known as | Kga-3235 free base | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314923 ↗ |
| Modality | Small molecule | — CHEMBL5314923 ↗ |
| Route | Oral | “orally administered mizagliflozin” NCT05541939 ↗ |